Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Trazodone
Drug ID BADD_D02266
Description Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants.[A181180] It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitor (SNRIs) in the treatment of depression.[T646] A unique feature of this drug is that it does not promote the anxiety symptoms, sexual symptoms, or insomnia, which are commonly associated with SSRI and SNRI therapy.[T646] Trazodone acts on various receptors, including certain histamine, serotonin, and adrenergic receptors, distinguishing it from other antidepressants that cover a narrow range of neurotransmitters.[T646] It was initially granted FDA approval in 1981.[L3484]
Indications and Usage For the treatment of depression.
Marketing Status Prescription; Discontinued
ATC Code N06AX05
DrugBank ID DB00656
KEGG ID D08626
MeSH ID D014196
PubChem ID 5533
TTD Drug ID D00USF
NDC Product Code 51655-634
Synonyms Trazodone | Tradozone | AF-1161 | AF 1161 | AF1161 | Deprax | Desyrel | Gen-Trazodone | Gen Trazodone | Molipaxin | Novo-Trazodone | Novo Trazodone | Trittico | PMS-Trazodone | PMS Trazodone | Ratio-Trazodone | Ratio Trazodone | RatioTrazodone | Thombran | Trazodon Hexal | Trazodon-Neuraxpharm | Trazodon Neuraxpharm | TrazodonNeuraxpharm | Trazodone Hydrochloride | Trazon | Apo-Trazodone | Apo Trazodone | Nu-Trazodone | Nu Trazodone
Chemical Information
Molecular Formula C19H22ClN5O
CAS Registry Number 19794-93-5
SMILES C1CN(CCN1CCCN2C(=O)N3C=CC=CC3=N2)C4=CC(=CC=C4)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Poisoning and toxicityCytochrome P450 2D6P10635T57392Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neuroleptic malignant syndrome17.05.02.003; 15.05.04.015; 12.03.01.003; 08.05.01.005--Not Available
Night sweats23.02.03.006; 08.01.03.031--Not Available
Nightmare19.02.03.003--Not Available
Ocular hyperaemia06.04.05.004--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oesophageal achalasia07.02.03.004--Not Available
Orgasm abnormal19.08.01.004; 21.03.02.013--
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Pain08.01.08.004--
Palpitations02.01.02.003--
Paraesthesia17.02.06.005--
Paranoia19.05.01.005--Not Available
Photophobia17.17.02.006; 06.01.01.004--
Photosensitivity reaction23.03.09.003--
Pollakiuria20.02.02.007--
Polyuria20.02.03.002--Not Available
Priapism21.03.01.0050.000135%Not Available
Pruritus23.03.12.001--
Psoriasis23.03.14.002; 10.02.01.036--Not Available
Rash23.03.13.001--Not Available
Retrograde ejaculation21.03.01.006--Not Available
Salivary hypersecretion07.06.01.009--Not Available
Sedation17.02.04.005--Not Available
Sensory loss17.02.07.007--Not Available
Serotonin syndrome17.05.02.004; 15.05.04.016; 12.03.01.041--Not Available
Sexual dysfunction19.08.05.002; 21.03.02.003--Not Available
Shock24.06.02.002--Not Available
Sinus bradycardia02.03.03.009--
Sinus congestion22.04.06.001--Not Available
Somnolence17.02.04.006; 19.02.05.0030.000224%
The 5th Page    First    Pre   5 6 7    Next   Last    Total 7 Pages